APA (7th ed.) Citation

Selke, J., Dzierma, Y., Manda, K., Hildebrandt, G., Frerker, B., Kalata, P., . . . Bock, F. (2026). Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC. Current Oncology, 33(6), 351. https://doi.org/10.3390/curroncol33060351

Chicago Style (17th ed.) Citation

Selke, Janne, Yvonne Dzierma, Katrin Manda, Guido Hildebrandt, Bernd Frerker, Paul Kalata, Christin Ackermann, and Felix Bock. "Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC." Current Oncology 33, no. 6 (2026): 351. https://doi.org/10.3390/curroncol33060351.

MLA (9th ed.) Citation

Selke, Janne, et al. "Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC." Current Oncology, vol. 33, no. 6, 2026, p. 351, https://doi.org/10.3390/curroncol33060351.